These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

While there is ongoing research to develop better tools like biochemical markers to differentiate fibrosis stage in MASH patients, the only standard currently used in MASH clinical studies involves ...

Black Diamond Therapeutics shows promise with BDTX-1535 for NSCLC treatment. Click here to find out why I rate BDTX stock a ...

Oncolytic viruses work by injecting genetic material into ... is planning a phase 2 trial of its RAS neoantigen vaccine TG01, targeting resected pancreatic cancer in combination with a checkpoint ...

A genetic fault long believed to drive the development of esophageal cancer may in fact play a protective role early in the disease. This unexpected discovery could help doctors identify which ...

A new study conducted at the Scojen Institute for Synthetic Biology at Reichman University's Dina Recanati School of Medicine ...

A surprising discovery reveals that a gene previously thought to accelerate esophageal cancer actually helps protect against it initially. This pivotal study could lead to better prediction and ...

There is therefore an urgent need for the development and testing of novel agents targeting pathways thought to be involved in the pathogenesis of breast cancer. Aberrant activation of the Ras/Raf ...

A genetic fault long believed to drive the development of esophageal cancer may in fact play a protective role early in the disease, according to new research published in Nature Cancer.

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study.

Cancer in children and adolescents is rare. Nevertheless, malignant diseases are still one of the most common causes of death ...

A new editorial was published in Oncotarget's Volume 15 on December 24, 2024, titled "Pitfalls and perils from FDA-approved germ-line cancer predisposition tests." ...